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medicine (CAM) users (87.3%) and participants below 50 
years old (81.1%) were identified as having a higher preva-
lence of ADRs compared to males (79.6%), CAM users (78.7%) 
and participants aged 50 years or more (77.5%). Patient age 
was found to be significantly associated (p = 0.048) with the 
ADRs. In addition, a total of 44 cases of DDIs belonging to 
category D were also found in this study.  Conclusions: This 
study enabled us to identify the most common ADRs and 
DDIs associated with the use of ART. Safe and effective treat-
ment depends on the healthcare providers’ knowledge of 
the same.  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Ever since the presence of human immunodeficiency 
virus (HIV) infection in central Africa in the year 1959, 
this incurable infection has changed the history of hu-
man health. According to the Joint United Nations Pro-
gramme on HIV/Acquired Immunodeficiency Syndrome 
(AIDS), there were 33.2 million people living with HIV 
in the year 2007 with a daily increment of 6,800 HIV cas-
es and about 5,700 cases of death from AIDS every day 
 [1] . In Malaysia, a total of 60,621 HIV and 8,840 AIDS 
cases have been reported between 1986 and 2004  [2] . A 
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 Abstract 
 Objective: This study aimed to explore the adverse drug re-
actions (ADRs) reported by patients and to identify drug-
drug interactions (DDIs) among human immunodeficiency 
virus/acquired immunodeficiency syndrome (HIV/AIDS) pa-
tients.  Subjects and Methods: This cross-sectional study 
was conducted at the Medication Therapy Adherence Clinic, 
Hospital Sungai Buloh, an HIV/AIDS referral centre. The pa-
tients were randomly selected and were encouraged to de-
scribe ADRs caused specifically by any of the prescribed an-
tiretroviral drugs (ARDs) . Sociodemographic characteristics 
were recorded from the patients’ medical records. In addi-
tion data on antiretroviral treatment (ART), DDIs and other 
conventional medication were also documented.  Results: A 
total of 325 randomly selected HIV/AIDS patients with a 
mean age of 22.94 years participated in the study. The most 
frequently prescribed ARDs were lamivudine (64.6%), zi-
dovudine (40.6%) and efavirenz (42.5%). Commonly report-
ed ADRs were fatigue (54.8%), allergic reactions (41.5%), 
weight loss (41.5%), dry mouth (35.1%) and memory loss 
(35.1%). Female (87.8%), non-complementary and alternative 
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survey in the USA reported that about 70% of individuals 
with HIV/AIDS were receiving antiretroviral treatment 
(ART)  [3] . In Malaysia, the number of HIV/AIDS patients 
receiving ART has increased from 1,710 people in 2003 to 
6,207 people in 2007  [4] . In 1996–1997 when ART was 
first introduced, approximately 50% of mortality reduc-
tion was shown among people living with HIV/AIDS who 
were compliant with the ART regimen  [5] .
 In spite of the benefits associated with the use of ART, 
the issues of drug-induced toxicities such as fat redistribu-
tion, dyslipidaemia, sexual dysfunction, insulin resistance 
and diabetes have remained of great concern which may 
lead to the non-compliance and discontinuation of ART 
 [6, 7] . For instance the use of non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs) has been associated with 
rash and hepatotoxicity  [7, 8] . Nucleoside reverse tran-
scriptase inhibitors (NRTIs) have been linked with hyper-
sensitivity reactions, anaemia and neutropenia  [9, 10] . 
Protease inhibitors have also been associated with hyper-
lipidaemia, hyperglycaemia and gastrointestinal symp-
toms  [6, 10, 11] . Furthermore, an increasingly complex 
drug therapy for HIV-infected patients not only increases 
the chances of adverse drug reactions (ADRs), but also 
provides ample potential for clinically significant drug in-
teractions  [12, 13] . Besides drug-drug interactions (DDIs) 
between prescribed drugs, there is evidence that garlic, St. 
John’s wort and vitamin C may reduce the concentration 
of antiretroviral drugs (ARDs)  [14] . Numerous other stud-
ies have also reported an interaction of ARDs such as sa-
quinavir and indinavir and complementary and alterna-
tive medicine (CAM) such as garlic and St. John’s wort  [15, 
16] . Nevertheless, it has been reported that awareness of 
pharmacological interaction and toxicity is lacking in 
some regions such as Africa  [14, 17] . However, this lack of 
awareness is not geographically confined to Africa, and it 
might be the same in other continents as well.
 To our knowledge, there has been no published data re-
garding self-reported ADRs and the potential DDIs in Ma-
laysian HIV/AIDS patients. Thus, the objectives of this re-
search were formulated to explore the occurrence of ADRs 
and DDIs among HIV/AIDS patients receiving ART.
 Subjects and Methods 
 This cross-sectional study was conducted on HIV/AIDS pa-
tients attending the Medication Therapy Adherence Clinic, Hos-
pital Sungai Buloh, an HIV/AIDS referral centre, Malaysia. The 
calculated sample size was 377 with an estimated drop-out rate of 
20% based on the total HIV/AIDS population (95,000) in Malay-
sia, confidence level and confidence interval (CI). The simple ran-
dom sampling technique was used, where randomization was car-
ried out using patients’ medical record numbers. Based on the 
randomization procedure adopted for this study, every fifth pa-
tient attending the clinic was selected from a pool of an average of 
60 patients/day. A total of 400 HIV/AIDS patients attending the 
clinics was randomly approached. However, at the end of the data 
collection phase, 325 patients agreed to be interviewed. Study pa-
tients with tuberculosis were excluded so as to minimize the im-
pact of confounding factors on the results. The sociodemograph-
ic factors of the patients attending the clinic were noted from the 
patients’ medical records and were later confirmed with the indi-
vidual patient at the start of the interview. In addition, data on 
ART, comorbidities and other conventional medication were al-
so recorded. Only those patients who were on ART for at least
1 month were included in this study.
 A 15- to 20-min interview was conducted at the Medication 
Therapy Adherence Clinic using the validated data collection 
form. The data collection form was distributed to 10 academic 
staff and 5 physicians to ascertain its content validity. The study 
information sheet was shown, and consent (either verbal or writ-
ten) was taken from all the recruited patients prior to the inter-
view. Subsequently, each participant was asked: ‘Are you diag-
nosed as having HIV/AIDS?’ and ‘Are you here to see the doctor 
for HIV/AIDS?’ It was done to ensure that the patient approached 
was the right patient to be interviewed. The patients attending the 
clinic were encouraged to describe ADRs caused specifically by 
any of the prescribed ARDs. In addition, confirmation of any ac-
tion taken to resolve the adverse reactions, and treatment pro-
vided to manage the condition from the clinic were also recorded. 
They were also asked about the current use of any CAM.
 The DDIs were also identified using 3 compendia: Microme-
dex, Hansten-Horn monographs and Lexi-comp online database. 
The classification provided in the Lexi-comp database is A, B, C, 
D, X; however, only D and X were considered clinically significant 
in this study. The recommendation for type D interactions was 
‘therapy modification’ and for type X interaction ‘contraindica-
tion’. Apart from ADRs and DDIs, risk factors associated with 
occurrence of ADRs were also identified.
 Both descriptive (means and standard deviation) and inferen-
tial data analyses (  2 for categorical variables, Spearman correla-
tion for non-normal distributed variables or Mann-Whitney for 
non-parametric data) were performed with the aid of SPSS  ver-
sion 13.0, and variables were taken as statistically significant at
p  ^  0.05. Related odds ratios (ORs) and 95% CIs allowed investi-
gation of independent risk factors associated with ADRs. The 
study was approved by the research and ethics committee. In ad-
dition, permission was also granted from the director of the hos-
pital, head of the infectious diseases department and pharmacy 
department. Information confidentiality was assured to all the 
study participants.
 Results 
 Sociodemographic Characteristics 
 A total of 400 people living with HIV/AIDS were ran-
domly approached at the Medication Therapy Adherence 
Clinic; however, only 325 patients agreed to be inter-
D
ow
nl
oa
de
d 
by
: 
14
9.
12
6.
78
.6
5 
- 1
/3
0/
20
16
 8
:5
8:
17
 P
M
 Adverse Drug Reactions and Drug-Drug 
Interactions among HIV/AIDS Patients 
Med Princ Pract 2011;20:265–270 267
viewed. The mean age was found to be 22.94  8 9.1 years. 
The age of more than half of the study participants (57%) 
was between 31 and 49 years. The majority of the partici-
pants were male (88%) and Chinese (56.6%). Moreover, 
58% were single and 68% had no children. The list of de-
mographic characteristics is presented in  table 1 . Among 
the study participants, almost 231 (71%) had received at 
least secondary school education. One hundred and sixty-
two (50%) were labourers while 70 (21.5%) were unem-
ployed. The majority of the participants (43.4%) disclosed 
their earnings between ringgit Malaysia (RM) 1,100 per 
month (USD 323) and RM 3,000 (USD 882). Two hundred 
and seventy (83%) were staying in urban areas; 88 (27%) 
were active smokers and 16 (4.9%) were alcoholics.
 Utilization Pattern of ART 
 All study participants were on ART, where lamivu-
dine (64.6%), zidovudine (40.6%) and stavudine (23.7%) 
were the top 3 prescribed NRTIs. Besides NRTIs, efavi-
renz (42.5%) and nevirapine (19.4%) were the only 2 
NNRTIs prescribed to the participants; however, they 
were found to be more frequently used (61.8%) than pro-
tease inhibitors (9.8%). With ARD combination therapy, 
zidovudine, lamivudine in combination with efavirenz 
(25.2%) was the most frequent combination prescribed to 
the study participants. In addition, about 30% of the pa-
tients were using some form of CAM.
 Comorbidities and Other Conventional Drugs 
 The most commonly found comorbidities in the study 
population were: hepatitis C, 16.6%; dyslipidaemia, 9.5%; 
toxoplasmosis, 8.3%; hepatitis B, 8.0%. Besides ART,
the top 3 drugs most frequently prescribed were sul-
phamethoxazole-trimethoprim in 28.6%, gemfibrozil in 
6.5% and chlorpheniramine maleate in 4.6%. 
 Patient-Reported Adverse Effects and DDIs  
 More than half of the study participants (178, 54.8%) 
reported to have fatigue after taking ART. The other fre-
quently reported ADRs were allergic reactions (135, 
41.5%), weight loss (135, 41.5%), dry mouth (114, 35.1%) 
and memory loss (114, 35.1%). The list of all ADRs re-
ported by the study participants is presented in  table 2 . 
Ten (22.7%) cases of an interaction between gemfibrozil 
and pravastatin were identified. Apart from that, 7 
(15.9%) cases of an interaction between indinavir and 
ritonavir, and 4 (9.1%) cases between itraconazole and 
efavirenz were also detected. 
 Relationship of ADRs with Study Factors 
 Gender (OR = 0. 541, CI = 0.203–1.440), CAM use
(OR = 0. 538, CI = 0. 251–1.151), ART (OR = 1.593, CI = 
Table 1. D emographic characteristics of the study population
(n = 325)
Variables Number Percent
Gender
Male 284 87.4
Female 41 12.6
Mean age, years       22.9489.114
Age groups
18–30 years 55 16.9
31–49 years 185 56.9
≥50 years 85 26.1
Ethnicity
Malay 87 26.8
Chinese 184 56.6
Indian 30 9.2
Other 24 7.4
Marital status
Single 188 57.8
Married 95 29.2
Divorced 29 8.9
Widowed 13 4.0
Children
Yes 105 32.3
No 220 67.7
Table 2. R ecord of patient adverse effect profile (n = 325)
Adverse effects Number Percent
Fatigue 178 54.8
Allergy 135 41.5
Weight loss 135 41.5
Dry mouth 114 35.1
Memory loss 114 35.1
Giddiness 98 30.2
Insomnia 91 28.0
Headache 89 27.4
Heatiness 82 25.2
Nausea and vomiting 71 21.8
Loss of appetite 65 20.0
Diarrhoea 45 13.8
Nightmare 43 13.2
Stomach ache 6 1.8
Foot loss sensation 6 1.8
Cold sweat 2 0.6
Mood swing 2 0.6
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0.896–2.834) and age less or more than 50 years (OR = 
1.242, CI = 0.559–2.761) were not found to be risk factors 
for the development of ADRs. However, age was found to 
be significantly associated (p = 0.048) and correlated (p = 
0.016) with the occurrence of ADRs. 
 Discussion 
 About 81% of the participants complained of experi-
encing ADRs, and this incidence rate was slightly higher 
compared to studies conducted by Sharma et al.  [18] 
(71.1%) and Johnson et al.  [19] (70%). The mean age of 
participants was 22.9 years which is significantly lower 
than in the study by Windi  [20] in Sweden (44.8 years) 
and the study conducted by Peltzer et al.  [17]  in South 
Africa (34.0 years). The majority of the participants were 
aged between 31 and 49 years, and this is consistent with 
the statistics of the Ministry of Health, Malaysia, for the 
year 2008, where 42.2% HIV-positive people were aged 
between 30 and 39 years  [21] . More than three quarters 
(87.4%) of participants were male which reflects the over-
all picture of HIV/AIDS in Malaysia as 80.9% of HIV/
AIDS cases in 2008 were male  [21] . Nevertheless, the 
numbers of females who were living with HIV/AIDS has 
noticeably increased about fivefold from 1986 to 2008 
 [21] . In this study, about 60% of the participants were 
Chinese; however, this picture did not reflect the real sit-
uation as Malays contributed to 67.5% of HIV and 56.8% 
of AIDS cases in the year 2006  [22] .
 In terms of socioeconomical characteristics, about 
71% of the participants in this study were found to have 
at least a secondary education level compared with par-
ticipants in Africa, in which only 29.9 and 20.5% of South 
Africans had at least a secondary school education  [17, 
23] . This is most likely due to the compulsory primary 
school education policy practice in Malaysia. Dyslipidae-
mia (9.5%) was one of the comorbidities suffered by study 
participants. It is supported by a study carried out in Ken-
ya, where 63.1% of the participants on stavudine, lamivu-
dine and either nevirapine or efavirenz were diagnosed 
to have dyslipidaemia  [6, 24] . Similarly, several studies 
have reported that use of protease inhibitors could be as-
sociated with hyperlipidaemia  [6, 18, 19, 25] .
 In Malaysia, any two drugs of choice from NRTIs in 
combination with any one drug of choice from NNRTIs 
are the first-line therapy. Common drugs of choice pre-
scribed to study participants from the NRTI class were 
lamivudine (64.6%), zidovudine (40.6%) and stavudine 
(23.7%), and this is almost similar to the report in 2003 
(lamivudine, 46%; zidovudine, 47%; stavudine, 43%) 
 [26] . Currently, there are only 2 NNRTIs available in Ma-
laysia, namely efavirenz and nevirapine. The current pre-
scription rate of efavirenz is 42.5% compared to 68% re-
ported by the National HIV/AIDS Treatment Registry. 
On the other hand, the prescription rate for nevirapine 
has increased from 6 to 19.4%  [26] . This might be due to 
the early introduction of efavirenz in the market (1999) 
compared to nevirapine (2001). Secondly it might also be 
due to the higher prevalence of rashes reported among 
people taking nevirapine than efavirenz  [7, 10, 11, 24, 26–
29] . In contrast to common ART practice in Taiwan, 
where 50.5% of the participants took an NRTI in combi-
nation with a protease inhibitor, most of the ART-receiv-
ing participants in this study were on NRTI in combina-
tion with NNRTI  [18] . About 25% of the ART-receiving 
participants (56.9%) were taking zidovudine and lamivu-
dine in combination with efavirenz. This is in line with 
the treatment guidelines by the Ministry of Health, Ma-
laysia, which recommends the use of 2 NRTIs (zidovu-
dine, lamivudine or stavudine) in combination with 1 
NNRTI (efavirenz)  [26] . A substantial number of patients 
(93) were on a sulphamethoxazole-trimethoprim combi-
nation for the treatment of pneumonia caused by  Pneu-
mocystis jiroveci  (carinii) , and this is particularly recom-
mended when the CD4 count drops below 200 cells/  l.
 The majority of ADRs described by the patients in this 
study could be disease originated; however, we empha-
sized on the report of ART-originated ADRs by patients. 
Similarly, ADRs such as hepatotoxicity and blood abnor-
malities may not have been reported by the patients in 
this study. Of all the reported adverse effects, fatigue 
(54.8%) was the most common ADR reported by the 
study participants, and this is consistent with the studies 
done in South Africa (55.7%) and Taiwan (65.1%)  [30, 31] . 
It has also been supported by Yeh et al.  [30]  where fatigue 
(54.9%) was the most commonly experienced ADR by the 
participants taking an NNRTI in combination with an 
NRTI. Since zidovudine and lamivudine are considered 
as first-line therapy in Malaysia, it is not surprising that 
fatigue is the most commonly reported ADR. However, 
one should not exclude the possibility of psychologically 
induced fatigue, associated with HIV/AIDS.  Allergic re-
actions constituted nearly 42% of the patients’ reported 
adverse effects. Nonetheless, not all the reported cases 
were medically significant for the physicians as 16.3% of 
participants who reported allergic reactions were given 
anti-allergic medicines such as chlorpheniramine male-
ate. Skin rash was commonly reported among individu-
als taking stavudine (18–30%), efavirenz (5–26%) and ne-
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virapine (50%) as the first-line therapy, which could ex-
plain the high occurrence of allergic reactions among the 
study participants  [24] . Like previous studies, weight loss 
(41.5%) was also a commonly reported ADR  [32] . Poor 
appetite and mouth ulcers were the reasons reported by 
patients which could result in weight loss.
 Higher incidences of ADRs were reported in partici-
pants who were on ART: 82.9% (189/228) of highly active 
ART users compared to 75.3% (73/97) of those not using 
highly active ART. Sharma et al. [18] stated that 50% of 
reported ADRs were related to zidovudine while stavu-
dine contributed 47.9% of reported ADRs. This is in con-
trast with the study of Paterson et al.  [32]  where only 0.2% 
of participants complained of ADRs like cough and diar-
rhoea after ART initiation. In addition, females (87.8%), 
non-CAM users (87.3%) and participants below the age 
of 50 years (81.1%) were identified as having a higher 
prevalence of ADRs compared to males (79.6%), CAM 
users (78.7%) and participants aged 50 years or above 
(77.5%). One of the possible explanations for younger pa-
tients having a higher prevalence is their greater number 
in the study population.
 Conclusions 
 The study could reflect a fair picture of the most com-
monly experienced ADRs with the use of ART in Malay-
sian HIV/AIDS patients. The uninformed and unpredict-
able ADRs may lead to non-adherence and ultimately 
treatment failure which poses a great necessity for the 
healthcare providers to be well equipped with the knowl-
edge of ADRs and to convey this knowledge to the pa-
tients in order to optimize the adherence and eventually 
efficacy of the treatment. Co-administration of ART for 
the treatment of HIV/AIDS and drugs to treat other co-
morbid conditions increases the risk of DDIs as was evi-
dent in this study. Therefore, successful execution of a 
safe and effective therapy also relies on the healthcare 
providers’ awareness on drug interaction potential, sig-
nificance of interactions and strategy to cope when such 
interactions occur.
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